Human medicines European public assessment report (EPAR): Ibandronic acid Accord, ibandronic acid, Date of authorisation: 18/11/2012, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzodeg, insulin degludec,insulin aspart, Date of authorisation: 21/01/2013, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Viramune, nevirapine, Date of authorisation: 04/02/1998, Revision: 45, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, Nivolumab,Relatlimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0458/2023

Human medicines European public assessment report (EPAR): Skyclarys, Omaveloxolone, Date of authorisation: 09/02/2024, Revision: 6, Status: Authorised

EMEA-003484-PIP01-23

Human medicines European public assessment report (EPAR): Mirvaso, brimonidine, Date of authorisation: 20/02/2014, Revision: 14, Status: Authorised

PSUSA/00002943/202406

Human medicines European public assessment report (EPAR): Anagrelide Viatris (previously Anagrelide Mylan), anagrelide, Date of authorisation: 15/02/2018, Revision: 11, Status: Authorised